Method of inhibiting microvascular thrombosis

Abstract

A method for reducing the thrombogenicity of microvascular anastomoses in a warm blooded mammal comprising administering to said mammal at the site of said microvascular anastomoses contemporaneously with microvascular reconstruction of a small but inhibitory effective amount of TFPI.

What is claimed is: 
     
       1. A method for reducing the thrombogenicity of microvascular anastomoses in a warm blooded mammal comprising administering topically to said mammal at the site of said microvascular anastomoses contemporaneously with microvascular reconstruction a small but inhibitory effective amount of from about 1 μg/ml to about 100 μg/ml applied in a volume of about 0.01 to about 1 ml volume of TFPI. 
     
     
       2. The method of claim 1 in which the TFPI is carried in a normal saline vehicle. 
     
     
       3. The method of claim 2 in which the TFPI is carried in said vehicle at a dose that does not affect the peripheral blood PT and APTT. 
     
     
       4. The method of claim 1 in which the TFPI is administered during microvascular reconstruction by free flap transfer. 
     
     
       5. The method of claim 1 in which the TFPI is administered during microvascular reconstruction by replantation. .Iadd. 
     
     
       6.  The method of claim 1 wherein said TFPI is a 277 amino protein having an alanine residue at its N-terminus. .Iaddend..Iadd.7. A method for reducing thrombogenicity of vascular injury in a warm blooded mammal comprising administering topically to said mammal at the site of said vascular injury a thrombotic inhibitory effective amount of tissue factor pathway inhibitor (TFPI). .Iaddend..Iadd.8. The method of claim 7 wherein said TFPI is a 277 amino acid protein having an alanine residue at its N-terminus. .Iaddend..Iadd.9. The method of claim 8 wherein said vascular injury occurs during vascular reconstruction by free flap transfer. .Iaddend..Iadd.10. The method of claim 8 wherein said vascular injury occurs during vascular reconstruction by replantation. .Iaddend..Iadd.11. The method of claim 7 wherein said TFPI is a 276 amino acid protein. .Iaddend..Iadd.12. The method of claim 7 in which said TFPI is carried in a saline vehicle. .Iaddend..Iadd.13. The method of claim 12 in which said TFPI is carried in said vehicle at a dose that does not affect the peripheral blood PT and APTT. .Iaddend..Iadd.14. The method of claim 7 wherein said vascular injury occurs during vascular reconstruction by free flat transfer. .Iaddend..Iadd.15. The method of claim 7 wherein said vascular injury occurs during vascular reconstruction by replantation. .Iaddend..Iadd.16. The method of claim 7 wherein said site of said vascular injury is a vein graft. .Iaddend..Iadd.17. A method for reducing thrombogenicity of vascular anastomoses in a warm blooded mammal comprising administering topically to mammal at the site of vascular anastomoses contemporaneously with vascular reconstruction a thrombotic inhibitory effective amount of tissue factor pathway inhibitor (TFPI). .Iaddend..Iadd.18. The method of claim 17 wherein said TFPI is a 277 amino acid protein having an alanine residue at its N-terminus. .Iaddend..Iadd.19. The method of claim 17 wherein said TFPI is a 276 amino acid protein. .Iaddend..Iadd.20. The method of claim 17 in which said TFPI is carried in a saline vehicle. .Iaddend..Iadd.21. The method of claim 20 in which said TFPI is carried in said vehicle at a dose that does not 
     
     
        affect the peripheral blood PT and APTT. .Iaddend..Iadd.22.  The method of claim 18 wherein said vascular anastomoses occurs during vascular reconstruction by free flap transfer. .Iaddend..Iadd.23. The method of claim 18 wherein said vascular anastomoses occurs during vascular reconstruction by replantation. .Iaddend..Iadd.24. The method of claim 17 wherein said vascular anastomoses occurs during vascular reconstruction by free flap transfer. .Iaddend..Iadd.25. The method of claim 17 wherein said vascular anastomoses occurs during vascular reconstruction by replantation. .Iaddend..Iadd.26. The method of claim 16 wherein said site of said vascular anastomoses is a vein graft. .Iaddend..Iadd.27. A method for reducing thrombogenicity of a traumatized vessel surface in a warm blooded mammal comprising administering topically to said mammal at the site of said traumatized vessel surface a thrombotic inhibitory effective amount of tissue factor pathway inhibitor (TFPI). .Iaddend..Iadd.28. The method of claim 27 wherein said TFPI is a 277 amino acid protein having an alanine residue at its N-terminus. .Iaddend..Iadd.29. The method of claim 28 wherein said vessel surface is traumatized during vascular reconstruction by free flap transfer. .Iaddend..Iadd.30. The method of claim 28 wherein said vessel surface is traumatized during vascular reconstruction by replantation. .Iaddend..Iadd.31. The method of claim 27 wherein said TFPI is a 276 amino acid protein. .Iaddend..Iadd.32. The method of claim 27 in which said TFPI is carried in a saline vehicle. .Iaddend..Iadd.33. The method of claim 32 in which said TFPI is carried in said vehicle at a dose that does not affect the peripheral blood PT and APTT. .Iaddend..Iadd.34. The method of claim 27 wherein said vessel surface is traumatized during vascular reconstruction by free flap transfer. .Iaddend..Iadd.35. The method of claim 27 wherein said vessel surface is traumatized during vascular reconstruction by replantation. 
     
     
        .Iaddend..Iadd.36.  The method of claim 27 wherein said traumatized vessel surface is a vein graft. .Iaddend.